Engineered Proteins

Engineered proteins are synthetic or modified biological molecules designed for specific therapeutic or diagnostic purposes, often optimized for stability, affinity, or novel functions (Nature Reviews Molecular Cell Biology, 2017). This broad category encompasses various modalities, including monoclonal antibodies, fusion proteins, and de novo designed scaffolds like DARPins or affibodies (Science, 2020). These molecules are developed using techniques such as directed evolution and computational modeling to address specific medical needs (Current Opinion in Biotechnology, 2021). In a clinical context, engineered proteins are used to modulate biological pathways by acting as agonists, antagonists, or enzyme replacements (PubMed, 2022). Because "Engineered Proteins" refers to a technology or a class of drugs rather than a specific biological entity like a receptor or enzyme, it is generally not classified as a single therapeutic target (NIH, 2023). Instead, these proteins are the agents designed to interact with specific targets to treat diseases such as cancer and autoimmune disorders.

Other names

Protein therapeuticsSynthetic proteinsDe novo proteinsRecombinant proteinsProtein scaffoldsDesigned proteins

Engineered proteins function as therapeutic agents by binding to specific biological targets to inhibit or activate signaling pathways, or by providing enzymatic functions that are deficient in the patient (Nature Reviews Drug Discovery, 2018).